LARTRUVO Concentrate for solution for infusion Ref.[8998] Active ingredients: Olaratumab

Source: European Medicines Agency (EU)  Revision Year: 2019  Publisher: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

Product name and form

Lartruvo 10 mg/mL concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion (sterile concentrate).

The concentrate is clear to slightly opalescent and colourless to slightly yellow solution without visible particles.

Qualitative and quantitative composition

One mL of concentrate for solution for infusion contains 10 mg of olaratumab.

Each 19 mL vial contains 190 mg of olaratumab.

Each 50 mL vial contains 500 mg of olaratumab.

Olaratumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.

Excipient with known effect:

Each 19mL vial contains approximately 22 mg (1 mmol) sodium.

Each 50 mL vial contains approximately 57 mg (2.5 mmol) sodium.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Olaratumab

Olaratumab is an antagonist of platelet derived growth factor receptor-α (PDGFR-α), expressed on tumour and stromal cells. Olaratumab is a targeted, recombinant, fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that specifically binds PDGFR-α, blocking PDGF AA, -BB, and CC binding and receptor activation. As a result, in vitro olaratumab inhibits PDGFRα pathway signalling in tumour and stromal cells. In addition, in vivo olaratumab has been shown to disrupt the PDGFR-α pathway in tumour cells and inhibit tumour growth.

List of Excipients

Mannitol (E421)
Glycine (E640)
Sodium chloride
L-Histidine monohydrochloride monohydrate
L-Histidine
Polysorbate 20 (E432)
Water for injections

Pack sizes and marketing

19 mL solution in a vial (Type I glass) with a chlorobutyl elastomeric stopper, an aluminium seal and a polypropylene cap.

50 mL solution in a vial (Type I glass) with a chlorobutyl elastomeric stopper, an aluminium seal and a polypropylene cap.

Pack of 1 vial of 19 mL.
Pack of 2 vials of 19 mL.
Pack of 1 vial of 50 mL.

Not all pack sizes may be marketed.

Marketing authorization holder

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

Marketing authorization dates and numbers

EU/1/16/1143/001-003

Date of first authorisation: 9 November 2016
Date of latest renewal: 21 September 2017

Drugs

Drug Countries
LARTRUVO Brazil, Estonia, Ireland, Lithuania, Poland, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.